Abstract:COVID-19 is a viral pandemic caused by SARS-CoV-2. Due to its highly contagious nature, millions of people are getting affected worldwide knocking down the delicate global socio-economic equilibrium. According to the World Health Organization, COVID-19 has affected over 186 million people with a mortality of around 4 million as of July 09, 2021. Currently, there are few therapeutic options available for COVID-19 control. The rapid mutations in SARS-CoV-2 genome and development of new virulent strains with increased infection and mortality among COVID-19 patients, there is a great need to discover more potential drugs for SARS-CoV-2 on a priority basis. One of the key viral enzymes responsible for the replication and maturation of SARS-CoV-2 is M-pro protein. In the current study, structure-based virtual screening was used to identify four potential ligands against SARS-CoV-2 M-pro from a set of 8,722 ASINEX library compounds. These four compounds were evaluated using ADME filter to check their ADME profile and druggability, and all the four compounds were found to be within the current pharmacological acceptable range. They were individually docked to SARS-CoV-2 M-pro protein to assess their molecular interactions. Further, molecular dynamics (MD) simulations was carried out on protein-ligand complex using Desmond at 100 ns to explore their binding conformational stability. Based on RMSD, RMSF and hydrogen bond interactions, it was found that the stability of protein-ligand complex was maintained throughout the entire 100 ns simulations for all the four compounds. Some of the key ligand amino acid residues participated in stabilizing the protein-ligand interactions includes GLN 189, SER 10, GLU 166, ASN 142 with PHE 66 and TRP 132 of SARS-CoV-2 M-pro. Further optimization of these compounds could lead to promising drug candidates for SARS-CoV-2 M-pro target.

SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

The SARS-CoV-2 main protease as drug target

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

A small molecule drug candidate targeting SARS-CoV-2 main protease

Progress in SARS-CoV-2, Diagnostic and Clinical Treatment of COVID-19

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

High-throughput Screening of SARS-CoV-2 Main and Papain-Like Protease Inhibitors

In silico identification of clinically approved medicines against the main protease of SARS-CoV-2, causative agent of covid-19

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

COVID-19: Discovery, diagnostics and drug development

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

De novo Design of SARS-CoV-2 Main Protease Inhibitors

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus

Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2

Structural Biology of SARS-CoV-2 Mpro and Drug Discovery.

Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics